| Trial ID: | L3533 |
| Source ID: | NCT00313001
|
| Associated Drug: |
Biphasic Insulin Aspart
|
| Title: |
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart|DRUG: exenatide
|
| Outcome Measures: |
Primary: Superiority as assessed by HbA1c reduction, at 24 weeks | Secondary: Safety variables|Patient satisfaction
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
373
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-04
|
| Completion Date: |
2007-07
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-06
|
| Locations: |
Novo Nordisk Investigational Site, Plainsboro, New Jersey, 08536, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00313001
|
